Browse the evidence

Tirzepatide likely results in a greater percentage reduction in body weight from baseline (mean difference -16.03, 95% CI -18.91 to -13.14) compared to placebo.

Practitioners can consider tirzepatide as an effective option for weight loss in adults with obesity.

Tirzepatide likely increases the number of people achieving a 5% weight reduction (risk ratio 3.60, 95% CI 2.44 to 5.30) compared to placebo.

Tirzepatide may be particularly effective for helping patients achieve significant weight loss goals.

Retatrutide administered at a 12 mg dosage resulted in significant reductions in body weight, body mass index, and waist circumference.

Practitioners can consider retatrutide as an effective treatment option for obesity.

A higher percentage of patients receiving retatrutide achieved weight losses of ≥5%, 10%, 15%, and 20% compared to placebo.

Retatrutide may be particularly effective for patients aiming for significant weight loss.

A reduction in liver fibrosis without worsening of steatohepatitis was reported in 36.8% of the patients in the semaglutide group compared to 22.4% in the placebo group.

Semaglutide may help reduce liver fibrosis in patients with MASH.

Tirzepatide (15 mg once weekly) resulted in weight loss of up to 17.8% after 72 weeks of therapy.

Tirzepatide is an effective option for weight loss in adults without diabetes.

Semaglutide (2.4 mg once weekly) resulted in weight loss of up to 13.9% after 68 weeks.

Semaglutide is a viable weight loss treatment for adults without diabetes.

GLP-1 receptor agonists and co-agonists are efficacious for weight loss with safety concerns predominantly gastrointestinal.

Practitioners should consider GLP-1 RAs for weight management, noting gastrointestinal side effects.

Semaglutide 2.4 mg weekly significantly reduces Major Adverse Cardiovascular Events (MACE) in obese patients without type 2 diabetes, independent of the magnitude of weight loss.

If you have obesity (BMI ≥ 27) but no diabetes, weekly semaglutide (2.4 mg) is a proven therapy to significantly lower your risk of heart attack, stroke, and cardiovascular death. This benefit happens through direct protection of your blood vessels and reduction of inflammation, not just by making you lose weight. To get the best results, you must pair the medication with a gradual dose increase to minimize stomach issues, and you must actively engage in resistance training and eat enough protein to prevent muscle loss.

GLP1-RA treatment is associated with improvements in restrained eating and emotional eating behavior compared with placebo.

GLP1-RAs may help improve eating behaviors in this population.

In the obesity cohort, maridebart cafraglutide resulted in a mean percent change in body weight from baseline to week 52 ranging from -12.3% to -16.2%, compared to -2.5% with placebo.

Maridebart cafraglutide may be an effective treatment option for weight loss in individuals with obesity.

In the obesity-diabetes cohort, maridebart cafraglutide resulted in a mean percent change in body weight from baseline to week 52 ranging from -8.4% to -12.3%, compared to -1.7% with placebo.

Maridebart cafraglutide may also be effective for weight loss in individuals with obesity and type 2 diabetes.

Tirzepatide would avert 45,609 obesity cases per 100,000 individuals over a lifetime.

Tirzepatide is effective in reducing obesity cases, suggesting its potential use in clinical practice.

Semaglutide would avert 32,087 obesity cases per 100,000 individuals over a lifetime.

Semaglutide is effective in reducing obesity cases, suggesting its potential use in clinical practice.

Semaglutide therapy resulted in a 62.9% resolution of MASH without worsening of fibrosis compared to 34.3% in placebo (p <0.001).

Clinicians can consider semaglutide as an effective treatment option for MASH with moderate-to-advanced fibrosis.

The oral formulation of semaglutide reduced AF incidence by 52%.

The oral formulation of semaglutide may be particularly effective in reducing AF risk.

Tirzepatide significantly decreased food intake and reduced overall appetite scores.

Tirzepatide may help reduce appetite, aiding in weight loss efforts.

NN1706 treatment led to 8.2% weight loss from baseline after 10 weeks in adults with overweight/obesity.

NN1706 may be an effective treatment option for weight loss in adults with overweight or obesity.

Incretin-based therapies resulted in significant reductions in body weight and/or body mass index in patients with obstructive sleep apnea.

Practitioners may consider incretin-based therapies as effective options for weight management in OSA patients.

GLP-1RA use in patients with metabolically unhealthy obesity (MUHO) is associated with a significantly lower risk of mortality (HR 0.580) compared to non-use.

Clinicians may consider GLP-1RAs for reducing mortality risk in MUHO patients.

Orforglipron has advanced through Phase 3 clinical development, demonstrating significant reductions in hemoglobin A1c and body weight (up to 7.9%) with favorable tolerability.

Practitioners can consider Orforglipron as an effective option for managing hemoglobin A1c and body weight.

GLP-1 receptor agonists (GLP-1RAs) and dual GLP-1 and glucose-dependent insulinotropic polypeptide receptor agonists (GLP-1/GIPRA) significantly reduce body weight and adiposity.

Practitioners can expect significant weight loss and reduction in adiposity with GLP-1RA and GLP-1/GIPRA therapies.

Correcting hormonal deficiencies may improve exercise capacity and reduce major cardiac events.

Clinicians should consider hormonal assessments in patients at risk of cardiovascular events.

Tirzepatide achieved up to 20.9% weight loss over 72 weeks in non-diabetic obese individuals.

Tirzepatide can be considered an effective option for weight management in non-diabetic obese patients.